Compare · JNJ vs LNDC
JNJ vs LNDC
Side-by-side comparison of Johnson & Johnson (JNJ) and Landec Corporation (LNDC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and LNDC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ carries a market cap of $680.19B.
- JNJ has hit the wire 14 times in the past 4 weeks while LNDC has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 5 for LNDC).
- Company
- Johnson & Johnson
- Landec Corporation
- Price
- -
- -
- Market cap
- $680.19B
- -
- 1M return
- +9.76%
- -
- 1Y return
- +39.68%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 1996
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 5
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Landec Corporation
Landec Corporation, together with its subsidiaries, engages in the design, development, manufacture, and sale of differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of plant-based salads, and fresh-cut and whole processed vegetables primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels to retail grocery chains, club stores, and food service operators; and sells BreatheWay packaging products. The Lifecore segment manufactures pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products to treat various medical conditions and procedures. It also provides product development services, including technology transfer, material component changes, analytical method and formulation development, pilot and stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It operates in the United States, Canada, Belgium, Switzerland, Czech Republic, Ireland, and internationally. The company was incorporated in 1986 and is headquartered in Santa Maria, California.
Latest JNJ
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
- EVP, Chief Legal Officer Forminard Elizabeth exercised 13,072 shares at a strike of $151.41 and sold $3,717,546 worth of shares (13,072 units at $284.39) (SEC Form 4)
- FDA Approval for LAZCLUZE issued to JANSSEN BIOTECH
- Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
- Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
- FDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECH
- Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Latest LNDC
- Landec Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form SCHEDULE 13G filed by Landec Corporation
- SEC Form SC 13G/A filed by Landec Corporation (Amendment)
- Schechter Joshua converted options into 9,554 shares, increasing direct ownership by 20% to 57,667 units (SEC Form 4)
- Calloway Nathaniel converted options into 3,981 shares, increasing direct ownership by 17% to 28,069 units (SEC Form 4)
- Obus Nelson converted options into 9,554 shares, increasing direct ownership by 12% to 88,687 units (SEC Form 4)
- Edwards Jeffrey L converted options into 9,554 shares, increasing direct ownership by 24% to 49,667 units (SEC Form 4)
- Diradoorian Raymond H converted options into 9,554 shares, increasing direct ownership by 31% to 39,978 units (SEC Form 4)
- Houde Lovas Katrina converted options into 9,554 shares, increasing direct ownership by 19% to 59,906 units (SEC Form 4)
- Barbarosh Craig A. converted options into 9,554 shares (SEC Form 4)